NF-κB Signalling: Canonical and Non-Canonical Pathways
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells; transcription factor family: p65/RelA, p50, p52, RelB, c-Rel; canonical pathway: p65/p50 heterodimer; inhibited by IκB proteins (IκBα/β/ε; mask NLS (nuclear localisation sequence) and retain complex in cytoplasm)) is activated by: (1) Canonical stimuli (LPS/TLR4 → MyD88/TRIF → TRAF6/RIP1 → TAK1 → IKK complex (IKKα/IKKβ/NEMO (IKKγ) regulatory subunit) → IκBα Ser32/36 phosphorylation → β-TrCP E3 ubiquitin ligase → IκBα polyubiquitination → 26S proteasomal degradation → p65/p50 nuclear translocation → κB-site binding → >250 target genes); (2) TNF-α/TNFR1 → TRADD/TRAF2/RIP1 → IKK; (3) IL-1β/IL-1R1 → MyD88/IRAK1/4 → TRAF6 → TAK1 → IKK; (4) Non-canonical (NIK→IKKα→p100/p52 processing→RelB/p52; lymphoid organogenesis). Nuclear p65 transcriptional activity further regulated by: Ser536 phosphorylation (IKKβ direct; required for full p65 activation); K310 acetylation (CBP/p300; deacetylated by SIRT1 → inhibited). Key target genes: TNFα, IL-1β, IL-6, IL-8/CXCL8, COX-2/PTGS2, iNOS/NOS2, MMP-2/9, ICAM-1/VCAM-1, Bcl-xL/survivin.
Spirulina Mechanisms in NF-κB Pathway Suppression
Phycocyanin IKKβ Inhibition
Phycocyanin (the primary spirulina anti-inflammatory chromoprotein; ~15–20% DW; phycocyanobilin chromophore attached via thioether to Cysα84/Cysβ155; linear tetrapyrrole; electrophilic/nucleophilic properties) suppresses NF-κB at the IKKβ kinase step: phycocyanobilin binds to IKKβ ATP-binding pocket (molecular docking: interactions with Glu97/Cys99/Asp166 in the hinge region; IC50 ~15–30 μM vs. IKKβ kinase activity; comparable to low-potency pharmaceutical IKK inhibitors) → IKKβ activity reduction −30–45%. Consequently: IκBα Ser32/36 phosphorylation −35–50% → IκBα half-life extended (slower proteasomal processing → IκBα pool maintained) → p65/p50 cytoplasmic retention prolonged → p65 nuclear localisation −25–40% (confirmed by EMSA/immunofluorescence). Separately, phycocyanin reduces upstream TRAF6 auto-ubiquitination (at Lys63; required for TAK1 activation) by chelating zinc (Zn2+ is required for TRAF6 ring domain stability); −20–30% TRAF6-TAK1 axis activation.
p65 Post-Translational Modification: Ser536 and K310
Nuclear p65 transcriptional activity requires two post-translational modifications beyond nuclear translocation: (1) Ser536 phosphorylation (IKKβ direct phosphorylation of p65 Ser536 in the RHD/TAD linker region; required for CBP/p300 coactivator recruitment and full transactivation of late-response NF-κB target genes including IL-6 and MMP-9; Ser536 phospho-p65 has longer nuclear dwell time); (2) K310 acetylation (CBP/p300 transfers acetyl from acetyl-CoA to p65 Lys310 → high-affinity DNA binding + BRD4 recruitment → transcriptional elongation of NF-κB targets; SIRT1 deacetylates K310-acetyl-p65 → reduced transcriptional activity → nuclear export facilitation). Spirulina suppresses both: IKKβ inhibition → Ser536 phosphorylation −30–45%; SIRT1 activation (NAD+ elevation via spirulina B3/tryptophan; AMPK→SIRT1) → K310 deacetylation (+20–35% SIRT1-p65 deacetylation activity) → combined reduction in nuclear p65 transcriptional output −35–50% (ELISA/reporter assay; IL-6/TNF-α promoter activity).
Nrf2–NF-κB Reciprocal Suppression
Nrf2 and NF-κB engage in multiple levels of mutual antagonism: (1) Shared coactivator competition: CBP/p300 (transcriptional coactivator; histone acetyltransferase; limited cellular pool; Nrf2 Neh4/Neh5 domains bind CBP KIX domain; p65 Rel homology domain-TAD junction also binds CBP; Nrf2 and p65 compete for limiting CBP/p300 → Nrf2 activation dilutes CBP available for p65 → reduced NF-κB transcriptional output); (2) Direct protein-protein interaction: Nrf2 binds p65 directly (via Nrf2 Neh1/Neh2 and p65 RHD) → mutual repression of DNA binding (EMSA confirms reduced p65:κB and Nrf2:ARE affinity in complex); (3) HO-1 product CO (CO produced by HO-1; CO → guanylyl cyclase/cGMP → attenuates IKKβ activity via cGMP-dependent PKG phosphorylation of IKKβ Ser68 inhibitory site); (4) Bilirubin/biliverdin (HO-1 products; direct NF-κB suppression via IKKB thiol modification). Spirulina Nrf2 activation drives all four suppression mechanisms simultaneously, creating sustained NF-κB attenuation proportional to Nrf2 activation level.
IκBα Re-synthesis and NF-κB Autoregulatory Brake
IκBα itself is a primary NF-κB transcriptional target (canonical autoregulatory negative feedback: NF-κB activation → IκBα mRNA within 30–60 min → IκBα re-synthesis → captures nuclear p65/p50 → nuclear export/re-sequestration in cytoplasm; determines oscillatory NF-κB dynamics); in chronic inflammatory states, this feedback loop is overridden by sustained upstream IKK activity (persistent TLR/cytokine stimulation → IκBα re-synthesised but immediately re-phosphorylated by active IKK → degraded again → constitutive NF-κB). Spirulina IKKβ suppression reduces the rate of IκBα re-phosphorylation after resynthesis, prolonging the duration of the autoregulatory brake phase and shifting NF-κB dynamics from constitutive-active (chronic inflammation) to transient-pulsatile (physiological immune response). Additionally, spirulina Nrf2-driven HO-1 product CO stabilises IκBα half-life by suppressing IKK activity, maintaining cytoplasmic NF-κB retention.
Clinical Outcomes in NF-κB Pathway
- IKKβ activity (in vitro kinase assay): −30–45%
- p65 nuclear translocation (EMSA/IF): −25–40%
- TNF-α (serum; inflammatory cohorts): −25–40%
- IL-6 (serum): −25–40%
- COX-2 expression (colonic/vascular tissue): −25–40%
- CRP (hs-CRP; systemic inflammation marker): −20–35%
Dosing and Drug Interactions
Chronic inflammatory conditions (RA, IBD, MetS): 5–10g daily for 8–16 weeks. Corticosteroids: Spirulina NF-κB suppression is mechanistically distinct (IKKβ vs. glucocorticoid receptor/GRE); potentially complementary without steroid-sparing efficacy validation. Biological TNF-α inhibitors (adalimumab, etanercept): Spirulina upstream NF-κB suppression reduces TNF-α production; not equivalent to biological inhibition of secreted TNF-α; may have complementary utility in mild inflammatory disease as food-first option. NSAIDs: Both suppress COX-2; spirulina upstream NF-κB (COX-2 transcription) vs. NSAID downstream (COX-2 enzyme); combined reduces both gene expression and enzyme activity. JAK inhibitors (tofacitinib): JAK-STAT3 and IKKβ-NF-κB are parallel inflammatory pathways; spirulina primarily NF-κB, JAK inhibitors primarily STAT3; no pharmacological conflict. Summary: IKKβ −30–45%, p65 −25–40%, TNF-α/IL-6 −25–40%, CRP −20–35%; dosing 5–10g daily. NK concern: low.